Bharat Biotech announced today that its Covid-19 vaccine, Covaxin, has received a certificate of Good Manufacturing Practice (GMP) compliance from the Hungarian authorities.
The approval has been received from the National Institute of Pharmacy and Nutrition, Hungary, certifying the GMP for the manufacture of Covaxin.
The certificate of GMP is now listed on the EudraGMDP database, which is the database of the European Community of manufacturing authorizations and certificates of the good manufacturing practice, the Hyderabad-based vaccine maker said.
Bharat Biotech intends to submit documentation for Emergency Use Authorization (EUA) in several additional countries worldwide.
With this approval, Bharat Biotech has achieved another significant milestone in innovating and manufacturing vaccines at global quality standards and moving forward in the ongoing fight against the Covid-19 pandemic.
The recognition complements our commitment of driving world-class innovation and being a frontrunner in the research and development of vaccines, it said.